**[미래에셋 제약/바이오 김승민]**
**10/26 Daily**

[https://t.me/bioksm](https://t.me/bioksm)


 **글로벌 바이오/제약**
────────────────────
 [J&J RYBREVANT FASPRO, 진행성 두경부암 1차 치료에서 77% 반응률 입증](https://www.jnj.com/media-center/press-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-combination-demonstrates-77-overall-response-rate-in-first-line-treatment-of-patients-with-advanced-head-and-neck-cancer)

 [Astrazeneca sone-ve 위암, 후기 시험서 전체 생존기간 연장 입증](https://news.google.com/rss/articles/CBMixwFBVV95cUxPQWE1d0RDaXR0T1dzS004NG1pSU9IVjEtNGF5VEVlY3hoVDh2eVYyLUZMZl93ckdRbnpkOVgyXzFXYzlyRmdZbWtaWnJXS2tuUWtNN2R6LXI3STllOWtwX2RVUTc2RUVPTmZhYlRsYWIwcWppeDVHdkRtUlVpRjB1QlVYUTNXSks3SDh4bGJsUkhjN2c0ZkpyNWlOcW0xbWFWSzZmQmpOYXBEYW5SY01CdWVjSEZMVXBtNUpRZjFLb0Z4T1ZCWmRB?oc=5)

 [J&J, 진행성 전립선암에서 JNJ-6143 RIPTIC 신약 75% 종양 반응률 달성](https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-75-tumor-response-rate-in-advanced-prostate-cancer-with-jnj-6143-a-first-in-class-riptac-molecule)

 [Amgen Imdelltra, 면역치료와 병용해 폐암 시험에서 생존기간 연장 입증](https://news.google.com/rss/articles/CBMixAFBVV95cUxQNkp5SkpQWTcySnpWVEtXVGN2azJZYnFERjh6WHJBR3NPcEE0TDNGWUVuQ0Q0WF91VnFFVkRYZjF1NFJ3N01XdzVTZzNXQ0F4NlVMMzVZY0JUNldtZW1CS0hSX3d4TUZVZ3lfX2xjeVF6UElWanluMXNOV05ybUdFb2YwbUJ2eGY3NkR0ZUhabWhaMGp5SERfajdZMzlUcGZsX3RULXNZMlI1eTMwbjFxWTlweW5uNHpNTWlVbmVKS2libTlG?oc=5)

 [BMS, 초기단계 세포치료제 임상시험에서 환자 사망 공개](https://news.google.com/rss/articles/CBMivgFBVV95cUxOclduTmpHbnJlZzEyZ21JQlNhMndRZFpOblcyR0VvbVFVdk5heXdnTUZxaWtGVzBPR0tGVUdhRWZKWlVQSFdKUGRwYjQtN1JIWWVZY0lJX3NYQkpEQV9HWmFPU0p0THdLb3N2aU1OWU10RGp5ODhPR3BMd01BdWRJRXRKalhVODFXcGl3OHVzaG5qTkxwNWl3clUtX3Q0ek5HQnloMUJJTmpKVXZ1b3ctc1gwTVd4ck5SUGJDS1ZR?oc=5)

 [Novartis, 다발성경화증 치료제 레미브루티닙 임상 재발 데이터 기대 이하로 발표](https://news.google.com/rss/articles/CBMi4AFBVV95cUxPbmp2bnQ0ZGNIb2puNWVPQ2thVDE1ajJjMTZObHhjMms5VHRubkNkNy1CaEVZd2lBTkhxNVp5NjJvVlZMT2RZOTVnYmZScWRMTW9NcWxIWWRpakZuX0dNem85V3g5dW1kN05DZ1g4VkRyd1hGdUxiQlFfYl81VUJwcElKNU5JS25Pd0F2R3RkTDU1ODZWZ2twNkZvSFNvWjRRdmw0S2xDQ2Z2bWJFT3lsdlJHTWI2dFhHOFBGUEVzN1VJYkRxNlR6OEVaS1I1MEVoTm5Ca0FtaXNISF9IMmdGTg?oc=5)

 [Zymeworks, 폐암 치료제를 로슈에 라이선스, 최대 8억 1,300만 달러 규모](https://news.google.com/rss/articles/CBMixgFBVV95cUxPOWkzclBOLWJneTk4MHV5NmdrOTdQb0gtS3JZNHV5d0V4Y1N1NXF0a1FLSjRWQmRHWjBndS1CaGhrdWhVZXN3eGRYdVgwbnQ1SUVmQWttelRyWktRbllnQVhJMGRHR0Z1aTFHTU9uU0MxSDdqdjBJOEhyeXRoMlgyeDlFaHAxXzZXeEhNcm84QlZBeVJ2TkNKcWh5Z05uUmRvOWNKRTJjTjhZOWpqYzluYm9LQkhxX3RiZWVra3E5NVlWNUF5NGc?oc=5)

 [Lilly 올로모라십, ESMO 2026에서 KRAS G12C 변이 비소세포폐암 1차 치료 내구성 데이터 공개](https://www.prnewswire.com/news-releases/new-data-on-lillys-investigational-treatment-olomorasib-at-esmo-2026-show-durable-first-line-activity-in-kras-g12c-mutant-non-small-cell-lung-cancer-302918479.html)


 **한국 바이오/제약**
────────────────────
 [한올바이오 '바토클리맙', 기술이전 9년 만에 중국 품목허가](https://www.hitnews.co.kr/news/articleView.html?idxno=80152)

 [[ESMO 2026]옥찬영 리가켐 센터장 “LCB02A, 클라우딘18.2 저발현 환자에도 효능 기대”](https://news.google.com/rss/articles/CBMibkFVX3lxTE1haXQ0T1hPRnZNdnlFS28xZ1FhalJnMW1vTTlraVpEREVJWmVKNWhBRE9ybk5DQXBvWnZPR2gxRnI4RjVaNXpnMS1EX21oNE5tM3pzNzVrS2N4UnZxRV8xVy1Mb3hMS3VGcjQxM1JR?oc=5)

 [디앤디파마텍 ‘페그세브레나타이드’, 뇌종양 전임상서 생존기간 60% 연장](https://news.google.com/rss/articles/CBMiWkFVX3lxTE9XSXRaTnhqeFhYQlBpYXZNNk1Bai1xV3VLcXdIR0FXUDJDS0RiT183MTFBYlhfaEh2WDJQdEp1T1Q1NjBKb1dRZmFITFhkUlZraEFEYV9BV0FvZw?oc=5)

 ["암백신 '인티스메란' 병용, 키트루다 대비 흑색종 재발∙사망 위험 42% 감소"](https://www.hitnews.co.kr/news/articleView.html?idxno=80174)

 [ESMO 기립박수 받은 임델트라+임핀지, 소세포폐암 표준 유지요법 부상](https://www.hitnews.co.kr/news/articleView.html?idxno=80172)

 [바토클리맙, 중국에서 전신 중증근무력증 신약 허가 획득](https://www.hitnews.co.kr/news/articleView.html?idxno=80131)

 [대웅제약 "펙수클루, 헬리코박터 제균 7일 요법 가능성 확인"](https://www.hitnews.co.kr/news/articleView.html?idxno=80126)

 [한미약품, 차세대 삼중 작용제 개발명 '잔트루타이드'로 결정 - 한국경제](https://news.google.com/rss/articles/CBMiWkFVX3lxTE9PVmE3Y0htZkQ1OE9uWllZeFB2djRhTFNrejZSVzYtTXQ2T0RVc0pIM0ZGcFFrMkRYOUxQWGVfbmh6NHktdkNDMGkta2owa2hmWVpucWhxUVdYUQ?oc=5)